On 15th December, the SME T-CURX GmbH announced the appointment of Thomas Loeser as the new CFO of the company and the attendance of the JPM 41st Annual Healthcare Conference 2023 in San Francisco from Jan 9-12, 2023.
Tom has served for more than 20 years as CFO of several European and US biotech companies, where he directed growth and financial strategies with particular emphasis on transatlantic company building and outreach to US capital markets.
In his last CFO position at Origenis GmbH/IZB Martinsried, Germany, Tom focused on the commercialization of its IP portfolio by the foundation of US-based Neuron23, Inc., dedicated to precision medicines for neurodegenerative diseases. Since its launch in 2019, Neuron23 has raised a total of $213 million from Kleiner Perkins, Westlake Village BioPartners, Perceptive Advisors, Softbank Vision Fund 2 and other high-profile VC/cross-over funds.
Prior to Origenis, Tom directed the financing strategy of ESBATech AG, Zurich, Switzerland. ESBATech, now a Novartis company, was recognized for its pioneering role in developing single-chain antibody fragments for ophthalmic indications by the support of a strong US-led venture capital syndicate since 2006 and the trade sale of its ophthalmology franchise to Alcon, Inc. for $589 million in 2009.
Read the full press release